Sanctuary Advisors LLC Invests $1.76 Million in Humana Inc. $HUM

Key Points

• Sanctuary Advisors acquired 4,439 Humana shares worth approximately $1.76 million in the second quarter. Institutional investors and hedge funds collectively own 92.38% of Humana’s outstanding stock.
• Humana reported quarterly EPS of $7.61, beating estimates of $7.27, while revenue rose 26.2% year over year to $40.89 billion.
• Analyst sentiment remains mixed: Humana has a consensus “Hold” rating and an average price target of $403.91, despite several firms raising targets and Leerink Partners upgrading the stock to “Outperform.”

Sanctuary Advisors LLC bought a new stake in shares of Humana Inc. (NYSE:HUM - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 4,439 shares of the insurance provider's stock, valued at approximately $1,763,000.

A number of other hedge funds have also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in Humana in the 2nd quarter valued at about $4,138,160,000. Pzena Investment Management LLC acquired a new position in shares of Humana in the 2nd quarter worth approximately $1,749,014,000. Capital International Investors raised its holdings in shares of Humana by 113.9% in the 4th quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider's stock worth $1,490,239,000 after purchasing an additional 3,097,571 shares in the last quarter. Norges Bank bought a new stake in shares of Humana in the 4th quarter worth approximately $456,632,000. Finally, Wellington Management Group LLP lifted its stake in Humana by 4,481.7% during the fourth quarter. Wellington Management Group LLP now owns 1,196,502 shares of the insurance provider's stock valued at $306,460,000 after purchasing an additional 1,170,387 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Stock Up 0.1%

HUM stock opened at $390.06 on Thursday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.74 and a quick ratio of 1.74. The firm has a market capitalization of $46.84 billion, a P/E ratio of 36.90, a P/E/G ratio of 2.22 and a beta of 0.72. Humana Inc. has a 52-week low of $163.11 and a 52-week high of $428.88. The company's 50 day simple moving average is $384.44 and its 200-day simple moving average is $286.38.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, topping analysts' consensus estimates of $7.27 by $0.34. Humana had a net margin of 0.88% and a return on equity of 11.20%. The firm had revenue of $40.89 billion during the quarter, compared to analyst estimates of $40.58 billion. During the same quarter last year, the business posted $6.27 EPS. The company's revenue was up 26.2% on a year-over-year basis. As a group, equities research analysts anticipate that Humana Inc. will post 9.12 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Leerink Partners upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $513.00 price target on the stock in a research report on Thursday, July 30th. The Goldman Sachs Group increased their price objective on Humana from $158.00 to $195.00 and gave the company a "sell" rating in a research report on Thursday, April 30th. JPMorgan Chase & Co. lifted their target price on Humana from $316.00 to $393.00 and gave the stock a "neutral" rating in a report on Monday, August 10th. Sanford C. Bernstein reaffirmed an "outperform" rating and set a $425.00 target price on shares of Humana in a research report on Wednesday, June 3rd. Finally, Barclays upped their target price on Humana from $344.00 to $407.00 and gave the company an "equal weight" rating in a report on Friday, July 31st. Fourteen equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $403.91.

About Humana

Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source